Ignite Creation Date:
2025-12-24 @ 6:42 PM
Ignite Modification Date:
2026-04-17 @ 12:18 AM
Study NCT ID:
NCT05411757
Status:
UNKNOWN
Last Update Posted:
2022-06-09
First Post:
2022-06-01
Is Gene Therapy:
True
Has Adverse Events:
False
Brief Title:
IBR900 Cell Injection Combined With Lenvatinib or Bevacizumab in the Treatment of Advanced Primary Liver Cancer
Sponsor:
Shandong Public Health Clinical Center
Organization:
Key Dates - Follows AllAPIJSON File Order
Start Date:
2022-06-30
Start Date Type:
ESTIMATED
Primary Completion Date:
2023-06-30
Primary Completion Date Type:
ESTIMATED
Completion Date:
2023-12-30
Completion Date Type:
ESTIMATED
First Submit Date:
2022-06-01
First Submit QC Date:
None
Study First Post Date:
2022-06-09
Study First Post Date Type:
ACTUAL
Results First Submit Date:
None
Results First Submit QC Date:
None
Results First Post Date:
None
Results First Post Date Type:
None
Results First Post QC Date:
None
Results First Post QC Date Type:
None
Disp First Submit Date:
None
Disp First Submit QC Date:
None
Disp First Post Date:
None
Disp First Post Date Type:
None
Last Update Submit Date:
2022-06-06
Last Update Post Date:
2022-06-09
Last Update Post Date Type:
ACTUAL